Akums Drugs and Pharmaceuticals IPO:
On July 30, 2024, Akums Drugs and Pharmaceuticals plans to launch its Initial Public Offering (IPO) to raise approximately Rs. 1,856.74 crore. This IPO is a significant event in the pharmaceutical sector, and understanding its details is crucial for potential investors. Below, we delve into the key aspects of the Akums Drugs IPO, including its structure, financials, and market positioning.
Akums Drugs and Pharmaceuticals IPO: Overview
- Opening Date:
July 30, 2024 - Closing Date:
August 1, 2024 - Price Band:
$646 to $679 per share - Lot Size:
A minimum of 22 shares is required, resulting in a $14,938 investment for retail investors. - Total Issue Size:
Approximately ₹1,856.74 crores, comprising a fresh issue of ₹680 crores and an offer for sale of ₹1,176.74 crores.
Akums Drugs and Pharmaceuticals IPO: Financial Performance
Despite recent challenges, Akums Drugs has shown resilience in its financial performance. For FY24, the company’s revenue grew nearly 14%, reaching ₹4,212.21 crores, although its profit-after-tax saw a significant decline of 99.1% to ₹79 lakh compared to the previous year. This discrepancy highlights the company’s ongoing efforts to manage costs and improve profitability.
Akums Drugs and Pharmaceuticals IPO: Key financial metrics
- Earnings per share (EPS):
<0x7E>0.28 - Return on Net Worth (RoNW):
-0.57% - Net Asset Value (NAV):
₹49.59 per share.
Akums Drugs and Pharmaceuticals IPO: Use of Proceeds
The IPO will allocate the funds raised towards:
- Repayment or prepayment of existing debt.
- Funding the incremental working capital requirements.
- Pursuing inorganic growth initiatives through acquisitions.
- General corporate purposes.
Akums Drugs and Pharmaceuticals IPO: Market position and competition
Akums Drugs is a prominent player in the Indian pharmaceutical contract development and manufacturing organisation (CDMO) market. It holds a substantial market share, with 29.4% by value in the domestic CDMO market as of FY23. The company competes with key players like Divi’s Laboratories, Gland Pharma, and Torrent Pharma.
Akums Drugs and Pharmaceuticals IPO: Competitive Advantages
- Manufacturing Capacity:
Akums boasts the largest production capacity among its peers, with 10 manufacturing plants capable of producing 49.23 billion units annually. - Diverse Product Portfolio:
The company offers a wide range of pharmaceutical products, including tablets, capsules, and injectables, catering to both domestic and international markets.
Akums Drugs and Pharmaceuticals IPO: Investment Considerations
Investors should weigh the potential benefits against the risks associated with the IPO. While Akums has a strong market presence and growth potential, it also faces challenges such as regulatory risks and reliance on third-party suppliers for raw materials.
READMORE: BHEL shares surge 3%: Massive order ignites investor enthusiasm
Grey Market Premium (GMP)
As the IPO approaches, monitoring the Grey Market Premium (GMP) can provide insights into investor sentiment and potential demand for the shares. A favourable GMP may indicate strong interest from investors, while a lower GMP could suggest caution.
Conclusion
The Akums Drugs and Pharmaceuticals IPO presents an opportunity for investors to engage with a leading player in the pharmaceutical sector. With a robust market position and strategic use of IPO proceeds, Akums aims to enhance its growth trajectory. However, potential investors should conduct thorough research and consider both the opportunities and risks before making investment decisions.